BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a leading biotechnology company specializing in therapies for rare genetic diseases. The company's strategic acquisition of Amicus Therapeutics for $4.8 billion is a significant move to enhance its market position against competitors like Alexion Pharmaceuticals and Vertex Pharmaceuticals.
Here are three key insights from the acquisition:
- BioMarin's acquisition of Amicus Therapeutics for $4.8 billion aims to strengthen its portfolio with Amicus' therapies, Galafold and Pombiliti-Opfolda, which generated $449 million in sales in the first nine months of 2025.
- The acquisition is financed through BioMarin's cash reserves and $3.7 billion in non-convertible debt, strategically avoiding equity dilution.
- Following the announcement, BioMarin's stock surged by 18%, reflecting investor confidence in the strategic benefits of the acquisition.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) focuses on developing and commercializing innovative therapies for rare genetic diseases. The company is known for its treatments for conditions like achondroplasia and severe hemophilia A, competing with companies like Alexion Pharmaceuticals and Vertex Pharmaceuticals in the rare diseases sector.
On December 23, 2025, Joon Lee from Truist Financial set a price target of $100 for BioMarin, while the stock was trading at $59.28. This suggests a potential upside of 68.7%. The announcement coincides with BioMarin's strategic acquisition of Amicus Therapeutics for $4.8 billion, expected to enhance its market position.
The acquisition involves purchasing all outstanding shares of Amicus at $14.50 per share in cash, a 33% premium over its previous closing price. Approved by both companies' boards, the deal is set to close in the second quarter of 2026. It will add Amicus' therapies, Galafold and Pombiliti-Opfolda, to BioMarin's portfolio, which generated $449 million in sales in the first nine months of 2025.
BioMarin plans to finance the acquisition using its cash reserves and $3.7 billion in non-convertible debt, avoiding equity dilution. This move aligns with BioMarin's strategy to expand its presence in the rare disease market. The acquisition also grants BioMarin U.S. rights to DMX-200, a late-stage drug for a rare kidney disease, further strengthening its pipeline.
Following the acquisition announcement, BioMarin's stock surged by 18%, while Amicus' stock increased by 30%. This reflects investor confidence in the strategic benefits of the acquisition. BioMarin's CEO, Alexander Hardy, emphasized that the deal aligns with the company's goals, leveraging its commercial and manufacturing capabilities in the lysosomal storage disorder space.
